Alex Sapir

Alex Sapir
  • Lecturer

Contact Information

  • office Address:

    Colonial Penn Center
    3641 Locust Walk
    Philadelphia, PA 19104

Links: CV

Overview

Alex Sapir, a thirty-year commercial executive of the pharmaceutical and biotech industry, most recently served as the CEO of ReViral, a venture-backed biotech company focused on anti-viral drug development, until the company was acquired by Pfizer in June 2022.  Prior to ReViral, Alex was the President and CEO at Dova Pharmaceuticals joining as employee #1 in December 2017.  Over a 24-month period, the company transformed to a 150-person fully integrated, revenue generating, publicly-traded biotech company.  In November 2019, Dova was acquired by Swedish Orphan Biovitrum AB (SOBI) for $900M.  Prior to Dova, Alex spent 10 years (2006-2016) at United Therapeutics as the Executive Vice President for Marketing and Sales.

Prior to his career in biotech, Alex worked at ZS Associates and GlaxoSmithKline.  He earned an M.B.A. from Harvard Business School and a B.A. in Economics from Franklin and Marshall College.

Alex currently serves on the Board of Directors for PhaseBio, a publicly-traded biotechnology company, and is a frequent guest lecturer at Duke University’s Fuqua School of Business where he leads case study discussions related to pharmaceutical marketing strategy.

Continue Reading

Teaching

Current Courses (Spring 2023)

  • HCMG8630 - Mgmt&econofpharm&biotech

    This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

    HCMG8630001 ( Syllabus )

  • HCMG2150 - Mgmt&econofpharma,biotec

    This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

    HCMG2150001 ( Syllabus )

All Courses

  • HCMG2150 - Mgmt&Econofpharma,Biotec

    This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

  • HCMG8630 - Mgmt&Econofpharm&Biotech

    This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

  • HCMG8990 - Independent Study

    Arranged with members of the Faculty of the Health Care Systems Department. For further information contact the Department office, Room 204, Colonial Penn Center, 3641 Locust Walk, 898-6861.

Knowledge at Wharton

How Analytics Can Boost Competitiveness in Sports

Wharton’s Eric Bradlow and FanDuel CEO Amy Howe discuss how analytics can benefit teams, players, and customers while ensuring the necessary data protections.Read More

Knowledge @ Wharton - 1/31/2023
How Jazz Can Unlock Your Team’s Next Breakthrough

“Generative conversations,” in which multiple perspectives are integrated to kindle new solutions, are a powerful way to address the complex challenges facing organizations. Experts from Wharton and SEB explain the neuroscience behind why they work.Read More

Knowledge @ Wharton - 1/27/2023
How to Use Neuroscience to Build Team Chemistry

In this Nano Tool for Leaders, Wharton's Michael Platt shares seven science-based ideas to help you create a high-performing team.Read More

Knowledge @ Wharton - 1/23/2023